Inhibrx Biosciences, Inc. - Common Stock (INBX)

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will retain Inhibrx’s non-INBRX-101 assets, for each share of Inhibrx that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will retain Inhibrx’s non-INBRX-101 assets, for each share of Inhibrx that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Inhibrx, Inc. (NASDAQ: INBX) to Sanofi is fair to Inhibrx shareholders. Under the terms of the proposed transaction, for each Inhibrx share, Inhibrx shareholders will receive $30.00 in cash, a contingent value right of $5.00, conditioned upon the achievement of a regulatory milestone, and 0.25 shares of a new publicly traded company that will retain Inhibrx’s non-INBRX-101 assets.

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all cancer-related deaths worldwide. Of concern, despite treatment, the mortality rates remain high and essentially unchanged over the last two decades. Furthermore, even in the setting […]